Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04720378
Recruitment Status : Active, not recruiting
First Posted : January 22, 2021
Last Update Posted : February 21, 2022
Sponsor:
Collaborator:
IQVIA Biotech
Information provided by (Responsible Party):
Noveome Biotherapeutics, formerly Stemnion

Brief Summary:
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.

Condition or disease Intervention/treatment Phase
Cytokine Release Syndrome Biological: ST266 Phase 1

Detailed Description:
This clinical trial will utilize a 3+3 enrollment design with sentinel approach.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection
Actual Study Start Date : May 30, 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : May 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1
0.1 ml/kg IV ST266 once a day for 5 days
Biological: ST266
1X ST266

Experimental: Cohort 2
0.25 ml/kg IV ST266 once a day for 5 days
Biological: ST266
1X ST266

Experimental: Cohort 3
0.5 ml/kg IV ST266 once a day for 5 days
Biological: ST266
1X ST266

Experimental: Cohort 4
1.0 ml/kg IV ST266 once a day for 5 days
Biological: ST266
1X ST266




Primary Outcome Measures :
  1. Incidence and Severity of Treatment-Emergent Adverse Events [ Time Frame: 3 months ]
    Determine the incidence and severity of treatment-emergent adverse events related to the IV administration of ST266 based on findings from physical examinations, laboratory evaluations, vital signs, and ECG measurements.


Secondary Outcome Measures :
  1. Pulse Oximetry [ Time Frame: 14 days ]
    Percent improvement in pulse oximetry from Baseline to Day 14

  2. Fever [ Time Frame: 14 days ]
    Time to resolution of fever

  3. Clinical Status on Ordinal Scale [ Time Frame: 14 days ]
    Improvement or absence of worsening in clinical status on WHO 7-point ordinal scale from baseline to Day 14


Other Outcome Measures:
  1. TNFα at Day 6 [ Time Frame: 6 days ]
    Change in TNFα from Baseline through Day 6

  2. IL- 1β at Day 6 [ Time Frame: 6 days ]
    Change in IL- 1β from Baseline through Day 6

  3. IL-6 at Day 6 [ Time Frame: 6 days ]
    Change in IL-6 from Baseline through Day 6

  4. TNFα at Day 14 [ Time Frame: 14 days ]
    Change in TNFα from Baseline through Day 14

  5. IL- 1β at Day 14 [ Time Frame: 14 days ]
    Change in IL- 1β from Baseline through Day 14

  6. IL-6 at Day 14 [ Time Frame: 14 days ]
    Change in IL-6 from Baseline through Day 14



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and non-pregnant/non-breastfeeding females age 18-70 years of age.
  2. Laboratory confirmed SARS-CoV-2 infection determined by PCR or other commercial/public health assay (test results must be obtained within 7-days of the Screening Visit).
  3. BMI between 18 and 39 inclusive, with a maximum weight of 150 kg (330lbs).
  4. Asymptomatic or mildly symptomatic COVID-19 positive subject with a score of 1 or 2 on the WHO 7-point ordinal scale.
  5. Subjects with pulse oximetry of > 94% on room air
  6. Subjects have controlled blood pressure of < 160/100 mmHg or systolic BP > 90 mmHg (or 20 mmHg less than usual range, whichever is higher)
  7. Subjects with pulse < 120 bpm
  8. Willingness and ability to comply with study-related procedures and assessments.
  9. If female, subjects must use an effective method of birth control or abstain from sexual relations with a male partner (unless has undergone tubal ligation or is 1 year postmenopausal) for their duration of study participation.
  10. If male, subjects must use an effective method of birth control or abstain from sexual relations with a female partner (unless has undergone a vasectomy and it has been more than 6 months) for their duration of study participation.
  11. Subject or subject's legal representative provides written consent prior to the initiation of any Screening or study specific procedures.

Exclusion Criteria:

  1. Subjects requiring immediate admission to the hospital due to complications of COVID-19 infection.
  2. Subject has an untreated active bacterial, fungal, viral or other infection not related to COVID-19 infection.
  3. Subjects with chronic lung diseases of any etiology including idiopathic pulmonary fibrosis, Tuberculosis, COPD, persistent asthma, and pulmonary hypertension.
  4. Subjects with a severe history of cardiac disease (such as congestive heart failure, coronary artery disease, cardiac arrhythmia)
  5. Subjects with a history of neurological disorders (such as epilepsy, stroke, encephalopathy, Guillain-Barré syndrome)
  6. Subjects with D-dimer > 2 ug/mL
  7. Subjects with a history of coagulopathy or currently taking anti-coagulation medication
  8. Subjects with PTT ≥ 100s or INR ≥ 2.75
  9. Malignancy in the last 5 years (except successfully treated basal cell carcinoma).
  10. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., eGFR < 30).
  11. Subjects with a reactive or positive screening test result For Hepatitis A virus immunoglobulin M (HAV IgM), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus Antibody (HCVAb) or Human Immunodeficiency Virus Antibody (HIVAb).
  12. TBIL> 2×ULN, ALT > 3×ULN, AST> 3×ULN, or ALP> 3×ULN.
  13. Neutrophils <1000/mm3, PLT<50×10^9/L, or HGB<8g/dL
  14. Previous participation in any other interventional clinical trial for the treatment for COVID-19.
  15. Subject actively participating in any other clinical study (with the exception of observational studies where there is no intervention with an investigational product or device)
  16. Use of anti-cancer or immunomodulatory biological drug or kinase inhibitor (e.g., tocilizumab, sarilumab) or, JAK inhibitors (within 30 days of enrollment or five times the half-life [whichever is longer]).
  17. Chronic glucocorticosteroid use equivalent to daily oral prednisone > 10 mg per day (10 mg oral prednisone every other day is allowed).
  18. Live (live-attenuated) vaccines are not permitted within 2 weeks prior to enrollment or during the study treatment and safety follow-up periods, including the SARS-CoV-2 vaccine (with the exception of the Flu vaccine which is allowed at any time)
  19. Subject is pregnant or breastfeeding or plans to become pregnant within 12 months.
  20. Subjects with a history of alcohol or drug abuse, or the use of illicit drugs within the 12 months prior to Screening or use of medical marijuana within 1 month prior to Screening.
  21. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04720378


Locations
Layout table for location information
United States, Florida
Innovative Research of West Florida
Clearwater, Florida, United States, 33756
United States, Illinois
Great Lakes Clinical Trials
Chicago, Illinois, United States, 60640
United States, Tennessee
WR-ClinSearch, LLC
Chattanooga, Tennessee, United States, 37421
Sponsors and Collaborators
Noveome Biotherapeutics, formerly Stemnion
IQVIA Biotech
Investigators
Layout table for investigator information
Study Director: David L Steed, MD Noveome Biotherapeutics, Inc
Layout table for additonal information
Responsible Party: Noveome Biotherapeutics, formerly Stemnion
ClinicalTrials.gov Identifier: NCT04720378    
Other Study ID Numbers: ST266-CRS-101
First Posted: January 22, 2021    Key Record Dates
Last Update Posted: February 21, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Noveome Biotherapeutics, formerly Stemnion:
COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Cytokine Release Syndrome
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Shock